ASH Data Bring UniQure Closer To Filing Hemophilia B Gene Therapy
Late-Breaking Data Suggest Activity At Level Needed For Approval
The company plans to file with 52-week data for AMT-061 and is confident it won't face the same stringent requirements from the FDA that led to a complete response letter for BioMarin's Roctavian.
